

**EMD Serono invites you to attend a promotional speaker program**



# A Treatment for Patients With *MET*ex14 Skipping Metastatic NSCLC



## The objectives of this program are:

- Review key lung cancer statistics and the role of *MET*ex14 Skipping Alterations in NSCLC
- Understand the latest treatment and testing guidelines in the treatment of eligible patients with mNSCLC
- Discuss the efficacy and safety of a treatment for patients with metastatic NSCLC harboring *MET*ex14 Skipping Alterations

**April Dumond, RN**  
MSN, RN, OCN, BMTCN  
Oncology Nurse Educator  
Oncology Nursing Associates

**Date:** December 13, 2022

**Time:** 6:00 PM Central

**Location:** Capital Grille  
500 crescent CT,  
Dallas, TX 75201  
214-303-0500



**Kristi Broumley**

**kristi.broumley@emdserono.com**

In compliance with the PhRMA Code on Interactions with Healthcare Professionals, guests and/or spouses will not be permitted to attend. For healthcare professionals licensed in Minnesota or Vermont, we regret that the laws of these states do not permit us to invite you to attend this event. Government employees should consult internal ethics guidelines before attending.

The value of this event's meal is subject to the tracking and transparency reporting requirements set forth by state and federal law.

MET, mesenchymal-epithelial transition; NSCLC, non-small cell lung cancer.

**No CNE or CME contact hours will be awarded.** This invitation is non-transferable.

©2021 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. US-TEP-00379. 10/21

**EMD  
SERONO**